Success Metrics

Clinical Success Rate

100.0%

Based on 11 completed trials

Completion Rate

100%(11/11)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

Ph phase_1

67%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution12 total trials

Phase 1Safety & dosage

8(66.7%)

Phase 2Efficacy & side effects

3(25.0%)

Phase 3Large-scale testing

1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

11 of 11 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(11)

Other(1)

Detailed Status

Completed11

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 18 (66.7%)

Phase 23 (25.0%)

Phase 31 (8.3%)

Trials by Status

unknown18%

completed1192%

Recent Activity

0 active trials

Showing 5 of 12

unknownphase_2

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

NCT00354276

completedphase_3

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00112554

completedphase_2

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

NCT00282022

completedphase_1

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

NCT00304005

completedphase_1

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

NCT00025129

View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials

NCT00354276Phase 2

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

Unknown

NCT00112554Phase 3

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

Completed

NCT00282022Phase 2

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Completed

NCT00304005Phase 1

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

Completed

NCT00025129Phase 1

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

Completed

NCT00049699Phase 1

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

Completed

NCT00083187Phase 2

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Completed

NCT00070538Phase 1

VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

Completed

NCT00098436Phase 1

Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

Completed

NCT00049686Phase 1

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

Completed

NCT00098761Phase 1

VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors

Completed

NCT00840684Phase 1

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Completed

All 12 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 12